Predict your next investment

ZENOAQ company logo
Corporation
HEALTHCARE | Biotechnology
zenoaq.jp

See what CB Insights has to offer

Investments

3

Portfolio Exits

1

Partners & Customers

3

About ZENOAQ

ZENOAQ is an animal health company that focuses on the R&D, manufacturing, and importation of animal health products, contributing to a broad product portfolio for production and companion animals.

ZENOAQ Headquarter Location

1-2-5 Kandasurugadai, Chiyoda-Ku 3rd Floor Surugadai Building

101-0062,

Japan

+81-3-5282-2485

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

ZENOAQ Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

ZENOAQ Rank

Latest ZENOAQ News

Global Pet Cancer Therapeutics Market 2021:Size,Share,Demand,Covid-19 Impact Analysis,Forecast To 2028||Key Players-Aratana Therapeutics, Inc., CanFel Therapeutics, Nippon Zenyaku Kogyo Co., Ltd., Morphogenesis, Inc

Mar 2, 2021

||Key Players-Aratana Therapeutics, Inc., CanFel Therapeutics, Nippon Zenyaku Kogyo Co., Ltd., Morphogenesis, Inc Data Bridge Market Research has recently added a concise research on the  Pet cancer therapeutics Market  to depict valuable insights related to significant market trends driving the industry. The report features analysis based on key opportunities and challenges confronted by market leaders while highlighting their competitive setting and corporate strategies for the estimated timeline. Some are the key & emerging players that are part of coverage and have being profiled are AB Science, Aratana Therapeutics, Inc., CanFel Therapeutics, Nippon Zenyaku Kogyo Co., Ltd., Morphogenesis, Inc., Rhizen Pharmaceuticals AG, Virbac, Pfizer Inc., VetDC, Boehinger Ingelheim International GmbH, Karyopharm, Elanco, VETCO, ELIAS Animal Health, Oasmia Pharmaceutical AB, Regeneus Ltd., Torigen Pharmaceuticals Inc., and Zoetis among other domestic and global players. Pet cancer therapeutics market research report assists organization gain vital information about the competitors, economic shifts, demographics, current market trends and spending traits of the customers. This global marketing report provides real world research solutions for every industry sector, along with meticulous data collection from non-public sources to better equip businesses with the information they need most. The report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Global Pet cancer therapeutics market report also covers five year industry forecasts, growth rates and an analysis of the industry key players and their market shares. Download Free Sample (350 Pages PDF) Report: To Know The Impact Of COVID-19 On This Industry@ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-pet-cancer-therapeutics-market Pet cancer therapeutics market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to USD 438.76 million by 2028 and will grow at a CAGR of 9.10% in the above mentioned forecast period. Patient Epidemiology Analysis Pet cancer therapeutics market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period. The rapidly increasing awareness of pet owners regarding pet diseases and rising willingness to spend on pet healthcare is amongst the important factors intensifying the growth and demand of pet cancer therapeutics market. In addition, the rising trend towards new product development is also contributing to the growth in the global market over the forecast period of 2021 to 2028. Also the increase in prevalence of cancer in pets, rising research and development expenditure and increasing trend of pet adoption are also enhancing the growth of the market. Likewise, the rising trend of pet adoption such as dogs and cats owing to the improved economic status of people are also lifting the market growth in the above mentioned forecast period. Also, the increasing prevalence of pet cancer and rising pet  healthcare  expenditure is also one of the significant factors fueling the growth of the pet cancer therapeutics market. The increase in various kinds of cancers in dogs and cats as well as the rapid surge in the funding of research activities pertaining to cancer therapy in canines and cat will further accelerate the expansion of the pet cancer therapeutics market and are also are offering significant growth opportunities for the market in the forecast period of 2021 to 2028. To Understand How Covid-19 Impact Is Covered In This Report, Get Free Covid-19 Sample@ https://www.databridgemarketresearch.com/covid-19-impact/global-pet-cancer-therapeutics-market Global Pet Cancer Therapeutics Market Scope and Market Size Pet cancer therapeutics market is segmented on the basis of therapy, medicine type, route of administration, cancer type, species type and end user. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications. On the basis of therapy, the pet cancer therapeutics market is segmented into chemotherapy, radiation therapy, immunotherapy, targeted therapy, combination therapy and others. On the basis of medicine type, the pet cancer therapeutics market is segmented into chemotherapy drugs and vaccines. Based on route of administration, the pet cancer therapeutics market is segmented into parenteral,  oral  and others. On the basis of cancer type, the pet cancer therapeutics market is segmented into melanoma, mast cell cancer, lymphoma, mammary and squamous cell cancer and others. The species type segment of pet cancer therapeutics market is segmented into cat, dog and others. Pet cancer therapeutics market is also segmented on the basis of end user into veterinary hospitals and clinical pharmacies, retail pharmacies, online pharmacies and others. Study Objectives Of Pet cancer therapeutics Market To provide detailed analysis of the market structure along with forecast for the next 7 years To study the factors affecting the Pet cancer therapeutics Market Growth To provide country level analysis of the Pet cancer therapeutics Market by their market size & future perspective To provide revenue forecast of the market segments & sub-segments w.r.t to three key region of APAC,EMEA & Americas To study & predict the accurate future market size, share during the period 2021-2028 To provide the challenges & restraints faced by the new entrants of Pet cancer therapeutics Market along with the threat of substitutes & threats of rivalry To study, track & analyze competitive developments such as joint ventures, strategic alliance, mergers, acquisitions & new product developments For More Information Or Query Or Customization Before Buying Visit@ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-pet-cancer-therapeutics-market Pet Cancer Therapeutics Market Country Level Analysis Pet cancer therapeutics market is analyzed and market size insights and trends are provided by country, therapy, medicine type, route of administration, cancer type, species type and end user as referenced above. The countries covered in the pet cancer therapeutics market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA). North America region leads the pet cancer therapeutics market owing to the rapid increase in the prevalence of pet cancer, well-established health care infrastructure and increasing research and development expenditure within the region. Asia-Pacific is expected to expand at a significant growth rate over the forecast period of 2021 to 2028 because of the growing incidence of pet cancer, increase in awareness, rising government initiatives and increase in disposable income within this particular region The Chapters Covered In Pet Cancer Therapeutics Market Report: Chapter 1: Pet cancer therapeutics Market Report 2021: Industry Overview, Definition, Specifications, Classification, Applications, Market Segment by Regions Chapter 2: Manufacturing Cost Structure Analysis of Pet cancer therapeutics: Raw Material and Suppliers, Manufacturing Cost Structure Analysis, Manufacturing Process Analysis and Industry Chain Structure Chapter 3: Technical Data and Manufacturing Plants Analysis of Pet cancer therapeutics: Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis of Global Pet cancer therapeutics Major Manufacturers in 2021 Chapter 4: Global Pet cancer therapeutics Overall Market Overview: 2021-2028 Overall Market Analysis, Capacity Analysis, 2021-2028 Global Pet cancer therapeutics Capacity and Growth Rate Analysis, 2021 Pet cancer therapeutics Capacity Analysis (Company Segment), Sales Analysis and Sales Price Analysis Chapter 5: Pet cancer therapeutics Market Regional Analysis: North America, China, Europe, Southeast Asia, Japan, India Chapter 6: Global 2021-2028 Pet cancer therapeutics Segment Market Analysis (by Type) Chapter 7: Global 2021-2028 Pet cancer therapeutics Segment Market Analysis (by Application) Chapter 8: Major Manufacturers Analysis of Pet cancer therapeutics Chapter 9: Development Trend of Analysis of Pet cancer therapeutics Market Chapter 10: Pet cancer therapeutics Marketing Type Analysis Chapter 11: Consumers Analysis of Pet cancer therapeutics Reasons To Purchase Pet Cancer Therapeutics Market Report Covered: The Pet cancer therapeutics market report analyses how market will progress in the coming years. Analyzing several views of the Pet cancer therapeutics market with the benefit of Porter’s five forces analysis. Identify the new progresses, Pet cancer therapeutics market shares and policies employed by the major market players. Study on the product type that is projected to dominate the market and regions that are expected to witness the fastest growth during the forecast period Competitive landscape including the Pet cancer therapeutics market share of major players along with the key strategies known for growth in the past five years Complete company profiles covering the product offerings, key financial information, recent developments, SWOT analysis and strategies employed by the major Pet cancer therapeutics market players About Us: Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing  sopan.gedam@databridgemarketresearch.com  . We are content with our glorious 99.9 % client satisfying rate. Contact:

ZENOAQ Investments

3 Investments

ZENOAQ has made 3 investments. Their latest investment was in Kringle Pharma as part of their Series E on March 3, 2020.

CBI Logo

ZENOAQ Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/2/2020

Series E

Kringle Pharma

$8.8M

No

CEJ Capital, DBJ Capital, Keio Innovation Initiative, M3, POC Clinical Research, TOHO Holdings, and TOHOKU University Venture Partners

3

12/5/2016

Series C

Subscribe to see more

$99M

Subscribe to see more

10

12/4/2007

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/2/2020

12/5/2016

12/4/2007

Round

Series E

Series C

Series B

Company

Kringle Pharma

Subscribe to see more

Subscribe to see more

Amount

$8.8M

$99M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Co-Investors

CEJ Capital, DBJ Capital, Keio Innovation Initiative, M3, POC Clinical Research, TOHO Holdings, and TOHOKU University Venture Partners

Sources

3

10

10

ZENOAQ Portfolio Exits

1 Portfolio Exit

ZENOAQ has 1 portfolio exit. Their latest portfolio exit was Kringle Pharma on December 28, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/28/2020

IPO

1

Date

12/28/2020

Exit

IPO

Companies

Valuation

Acquirer

Sources

1

ZENOAQ Partners & Customers

3 Partners and customers

ZENOAQ has 3 strategic partners and customers. ZENOAQ recently partnered with Immunomic Therapeutics on February 2, 2019.

Date

Type

Business Partner

Country

News Snippet

Sources

2/6/2019

Licensor

Immunomic Therapeutics

United States

Immunomic Therapeutics Licenses Investigational Canine Dermatitis Therapy to ZENOAQ

ZENOAQ 's partners include Boehringer Ingelheim Animal Health , CEVA SA , Vetoquinol , Mars , Intervet , DSM Nutrition as well as IDEXX Laboratories .

2

5/18/2016

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

7/25/2013

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

2/6/2019

5/18/2016

7/25/2013

Type

Licensor

Partner

Partner

Business Partner

Immunomic Therapeutics

Country

United States

Subscribe to see more

Subscribe to see more

News Snippet

Immunomic Therapeutics Licenses Investigational Canine Dermatitis Therapy to ZENOAQ

ZENOAQ 's partners include Boehringer Ingelheim Animal Health , CEVA SA , Vetoquinol , Mars , Intervet , DSM Nutrition as well as IDEXX Laboratories .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.